The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon
Language English Country England, Great Britain Media print
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Time Factors MeSH
- Diverticulum, Colon drug therapy therapy MeSH
- Escherichia coli * MeSH
- Remission Induction MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Probiotics therapeutic use MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
BACKGROUND: The effect of probiotics in symptomatic uncomplicated diverticular disease of the colon has not been followed. DESIGN: Treatment (T1) with an intestinal antimicrobial (dichlorchinolinol) and absorbent (active coal tablets) was compared with the same set-up supplemented with non-pathogenic Escherichia coli(T2) in a prospective open trial. SETTING: The study was performed at the outpatient department of a tertiary centre. PARTICIPANTS: Fifteen subjects (5 males, 10 females) aged 68-91 years (average 74.8 years) presented with abdominal pain, irregular defecation, bloating and excessive flatulence. Diagnosis was established with colonoscopy, double-contrast barium enema, or both. INTERVENTIONS: The T1 regimen was administered for 1 week. In the T2 regimen, the application of E. coli strain Nissle (Mutaflor capsules, 2.5 x 10(10) viable bacteria/capsule) followed immediately after T1 for an average of 5.2 weeks. MAIN OUTCOME MEASURES: The lengths of two successive remissions with the T1 set-up were compared with the length of remission after T2. The intensity of symptoms before and after administration of the probiotic was also evaluated. RESULTS The lengths of two successive remissions after T1 amounted to 2.66 and 2.20 months (average 2.43 months). The average length of remission after T2 was 14.1 months (P < 0.001). All symptoms after T2 decreased significantly (P < 0.001). CONCLUSIONS: Non-pathogenic strain Nissle significantly prolonged the remission period and improved the abdominal syndrome in symptomatic uncomplicated diverticular disease. A randomized, placebo-controlled study is recommended.
References provided by Crossref.org